---
id: 061
title: IV Fosfomycin and Biofilm Activity
category: antimicrobials
subcategory: fosfomycin
tags: [fosfomycin, IV, biofilm, osteomyelitis, prosthetic-joint, off-label]
difficulty: hard
---

## Question

What is the role of **IV fosfomycin** for systemic infections and biofilm-associated infections? Use the **"NOT in US - But BIOFILM Active"** mnemonic.

## Answer

### **"NOT in US - But BIOFILM Active" Mnemonic:**

**NOT in US:**
- **N**ot FDA approved for IV use
- **O**ral formulation only in USA
- **T**issue levels inadequate with PO

**But BIOFILM Active:**
- **B**iofilm penetration excellent
- **I**V available internationally (Europe, Asia)
- **O**steomyelitis off-label use
- **F**oreign body infections (PJI)
- **I**n combination therapy (daptomycin, β-lactam)
- **L**ow molecular weight → good penetration
- **M**DR Gram-negative infections

**Active** = Synergy with other agents for resistant infections

### **IV vs Oral Fosfomycin:**

| Feature | Oral (USA) | IV (International) |
|---------|------------|-------------------|
| **FDA approved in US** | ✅ YES | **❌ NO** (not available) |
| **Bioavailability** | 37-41% (low) | 100% (IV) |
| **Serum levels** | Low | High (adequate for systemic) |
| **Indication (USA)** | Uncomplicated cystitis only | N/A (not approved) |
| **Off-label use** | Limited | Systemic infections, biofilms |
| **International availability** | Limited | Widely available (EU, Asia) |

### **Biofilm Penetration:**

**Why Fosfomycin is Unique for Biofilms:**

1. **Small molecular weight** (138 Da) → excellent tissue/biofilm penetration
2. **Penetrates interior of biofilms** (unlike most antibiotics)
3. **Kills non-replicating bacteria** within biofilm
4. **Synergy with other agents** (daptomycin, β-lactams, colistin)

**Evidence for Biofilm Activity:**
- Good activity against **biofilm-producing *E. coli*, *Enterococcus*, *S. aureus***
- **ESBL *E. coli* foreign-body model**: Fosfomycin + colistin → 67% cure rate
- Penetrates prosthetic joint biofilms

### **Off-Label Uses (Mainly International with IV Formulation):**

| Infection | Fosfomycin Role | Notes |
|-----------|-----------------|-------|
| **Prosthetic joint infection (PJI)** | Combination therapy | + rifampin or fluoroquinolone |
| **Osteomyelitis with hardware** | Biofilm penetration | Emerging data (2024) |
| **MRSA endocarditis** | + daptomycin (synergy) | Prevents daptomycin resistance |
| **CNS infections** | Good CSF penetration | International use (IV) |
| **MDR Gram-negative bacteremia** | Combination therapy | + β-lactam or carbapenem |
| **Complicated UTI/pyelonephritis** | Multi-dose oral regimen | 3g q48-72h (controversial) |

### **Combination Synergy:**

**Fosfomycin + Daptomycin:**
- **Prevents daptomycin resistance** in *S. aureus*
- **Synergistic killing** against MRSA biofilms
- Used for complicated MRSA bacteremia/endocarditis

**Fosfomycin + β-lactams/Carbapenems:**
- **Synergy** against MDR Gram-negatives
- Useful for CRE, MDR *Pseudomonas*

**Fosfomycin + Colistin:**
- Biofilm eradication in ESBL *E. coli*
- Foreign-body infections

## Key Points

### **International IV Dosing (Not Approved in US):**

**Standard IV Dose (International):**
- **12-24 grams/day IV** divided q6-8h
- Higher doses for CNS infections: 16-24 g/day

**Availability:**
- Europe: Widely available (IV fosfomycin disodium)
- Asia: Available
- **USA: NOT AVAILABLE** (only oral formulation approved)

### **US Alternative: Multiple-Dose Oral Fosfomycin (Off-Label):**

**Regimen for Complicated UTI (Controversial):**
- 3g PO **every 2-3 days** × 2-4 weeks
- Example: Day 1, 3, 5, 7, etc.
- **Not officially recommended by IDSA** (inadequate serum levels)
- Some case reports show efficacy

### **Resistance Mechanisms:**

**Why Fosfomycin Must Be Used in Combination:**

1. **Rapid resistance** if used as monotherapy
2. Mutations in:
   - **fosA** gene (glutathione transferase) → drug inactivation (*K. pneumoniae*)
   - **glpT/uhpT** genes → reduced uptake
   - **murA** gene → altered target

**Clinical Pearl:** **NEVER use fosfomycin monotherapy** for systemic infections

### **2024 Updates:**

**Bone and Joint Infections (Emerging Use):**
- IV fosfomycin shows promise for biofilm-associated bone/joint infections
- Used in combination with rifampin, fluoroquinolones, or β-lactams
- Good bone penetration

**IDSA 2024 Guidance:**
- Fosfomycin **NOT suggested** for pyelonephritis or complicated UTI (US oral formulation)
- **Alternative** for ESBL *E. coli* **cystitis only**
- **DO NOT use** for *K. pneumoniae* (fosA resistance)

### **Clinical Pearls:**
- **US limitation:** Only oral formulation available (limits use to uncomplicated cystitis)
- **Biofilm activity** makes it attractive for PJI, osteomyelitis (need IV formulation)
- **Always combine** with another agent to prevent resistance
- **Synergy with daptomycin** prevents daptomycin resistance in MRSA
- **Unique mechanism** → retained activity against ESBL, MRSA, VRE
- **Small molecular weight** → excellent tissue/biofilm penetration

### **When IV Fosfomycin Would Be Ideal (If Available in US):**
- Prosthetic joint infection with MRSA/Enterococcus
- MRSA endocarditis (+ daptomycin)
- MDR Gram-negative osteomyelitis
- CNS infections (good CSF penetration)
- Biofilm-associated device infections

## Sources

- [MDPI 2024: IV Fosfomycin for Biofilm-Associated Bone/Joint Infections]
- [PMC6555168: Fosfomycin in MDR Gram-Negative Infections]
- [IDSA 2024: AMR Guidance Version 3.0]
- [CMR 2016: Fosfomycin Review]

## Media

N/A
